Dunad Therapeutics is a biopharmaceutical company focusing on the development
of next-generation targeted oral protein degradation therapies
Dunad’s unique small molecule platform induces targeted degradation of disease-causing and often undruggable protein targets via direct modulation of protein stability and conformation. The Company’s novel molecular approach is fully tuneable to be exquisitely selective and underpinned by a target-class agnostic mechanism of action that is distinct from other targeted protein degradation technologies.
This has the potential to generate orally bioavailable degrader therapeutics that significantly expand the frontiers of protein degradation targets.
Dunad was founded in 2020 and is headquartered in Cambridge, UK with operations in both the UK and North America. The company is backed by founding investor Epidarex Capital as well as BioGeneration Ventures (BGV) and Novartis.
The Company is further building the platform, enhancing its proteomics and bioinformatics infrastructure and expanding its proprietary library of covalent degraders with the aim to advance its emerging pipeline of novel therapeutics, predominantly focused on oncology and CNS indications.
In November 2021 Dunad announced a strategic partnership with Novartis to develop next-generation oral covalent and protein degrading small molecule drugs across multiple target classes, leveraging Dunad’s proprietary platform. Novartis has an exclusive option to license, develop and commercialize resulting candidates for up to four targets.